Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android

For further information, see CMDT Part 36-14: Mycetoma (Eumycetoma & Actinomycetoma)

Key Features

  • Mycetoma is a chronic local, slowly progressive, destructive infection

  • Begins in subcutaneous tissues, frequently after implantation trauma, and spreads to contiguous structures with sinus tracts and extruding grains

  • Eumycetoma (also known as maduromycosis) is mycetoma caused by true fungi

  • Actinomycetoma is mycetoma caused by Actinomadura, Streptomyces, and Nocardia

Clinical Findings

  • Lesion begins as a papule, nodule, or abscess that, over months to years, forms multiple abscesses and sinus tracts ramifying deep into the tissue

  • Secondary bacterial infection may occur in large open ulcers


  • Radiographs may show destructive changes in underlying bone

  • Causative species can often be suggested by the color of the characteristic grains and hyphal size within the infected tissues

  • Definitive diagnosis requires culture


  • Prognosis of eumycetoma is poor

    • However, surgical debridement with prolonged oral itraconazole therapy (200 mg twice daily) or combination therapy including itraconazole and terbinafine yields a response rate of 70%

    • Amputation is necessary in far-advanced cases

  • For actinomycetoma

    • Trimethoprim-sulfamethoxazole, 8/40/mg/kg/day orally for 5 week cycle plus

    • Amikacin, 15 mg/kg/day intravenously or intramuscularly in two divided doses for first 3 weeks of cycle

    • Debridement assists healing

  • Prognosis of actinomycetoma is good because it usually responds to sulfonamides plus aminoglycosides

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.